Unraveling the Mysteries of Cystic Fibrosis: Causes, Symptoms, and Treatment Strategies

Main Article Content

María Fernanda Gámez Acosta
Ingrid Pamela Rodríguez Minguela
Ivan Fernando López Álvarez
Alejandra Zermeño Medina
Jorge Baltazar Márquez Martínez
Ana Luisa Brito González
Alejandro Herbert Oliva Arvizu

Abstract

In this work we present the most relevant and important data, so that the reader will be able to identify the disease "Cystic Fibrosis", regardless of the fact that in Mexico this disease is not common, thanks to the fact that in Mexico and in the world newborns are screened. In this way the rate of this disease in Mexico and the world was reduced.


In Mexico, there are 350 new cases every year, said the General Director of the National Center for Gender Equity and Reproductive Health, Dr. Ricardo García Cavazos. Thanks to this data, the purpose of this work is to guide readers in the identification of this disease and in this way generate a positive and active influence in the identification of this disease.


This disease is a disease that has its historical antecedents since the year 1595, when with the thought of a spell on a girl during her autopsy, the first clinical data that are characteristic of this disease were given. Being in the 70's where with the passage of time and as new knowledge came to what we know today.


Cystic fibrosis is an inherited multisystem disorder of children and adults, it is the leading cause of severe chronic lung disease in children. Cystic fibrosis occurs most often in white populations in Northern Europe, North America and Australia/New Zealand and is inherited in an autosomal recessive manner.

Article Details

How to Cite
María Fernanda Gámez Acosta, Ingrid Pamela Rodríguez Minguela, Ivan Fernando López Álvarez, Alejandra Zermeño Medina, Jorge Baltazar Márquez Martínez, Ana Luisa Brito González, & Alejandro Herbert Oliva Arvizu. (2023). Unraveling the Mysteries of Cystic Fibrosis: Causes, Symptoms, and Treatment Strategies. International Journal of Medical Science and Clinical Research Studies, 3(11), 2582–2586. https://doi.org/10.47191/ijmscrs/v3-i11-07
Section
Articles

References

I. Kliegman, R. M., MD, Stanton, B. F., MD, St Geme III, J. W., MD, & Schor, N. F., MD,PHD. (2016). Treatise on pediatrics (20th ed.). Madrid: Elsevier.

II. Lay, C., Law, N., Holm, A. M., Benden, C., & Aslam, S. (2019). Outcomes in cystic fibrosis lung transplant recipients infected with organisms labeled as pan-resistant: An ISHLT Registry-based analysis. The Journal of Heart and Lung Transplantation. doi:10.1016/j.healun.2019.01.1306.

III. Ravaglia, C., Bosi, M., Wells, A. U., Guriolioli, C., Guriolioli, C., Dubini, A., . . . Poletti, V. (2019). Idiopathic pulmonary fibrosis: prognostic impact of histologic honeycombing in transbronchial lung cryobiopsy. Multidisciplinary Respiratory Medicine, 14(1). doi:10.1186/s40248-019-0170-y.

IV. Robbins, Cotran, Kumar V, Abbas A, Aster J. Structural and functional pathology. 9th ed. Amsterdam: Elsevier; 2015.

V. Thompson, V., Mayer-Hamblett, N., Kloster, M., Bilton, D., & Flume, P. (2015). Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study. Journal of Cystic Fibrosis, 14(5), 632-638. doi:10.1016/j.jcf.2015.02.003.

Most read articles by the same author(s)